Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Tazemetostat for relapsed/refractory follicular lymphoma - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Tazemetostat for relapsed/refractory follicular lymphoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Indication: Tazemetostat for relapsed/refractory follicular lymphoma

New Indication: Tazemetostat for relapsed/refractory follicular lymphoma
Study:
  • Single-arm phase 2 trial
  • Relapsed or refractory to >=2 systemic therapies
  • EZH2 mutant (n=45) and EZH2 WT (n=54) categories
Efficacy:
  • EZH2 mutant and EZH2 WT
  • ORR: 69% (53-82%) and 35% (23-49%)
  • Median DoR: 10.9 mos (7.2 mos – not estimable) and 13.0 mos (5.6 mos – not estimable)
Safety:
  • Grade >=3 adverse events: Thrombocytopenia (3%), neutropenia (3%), anemia (2%)

Lancet Oncology 2020 Oct 6. Online ahead of print.

Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

https://doi.org/10.1016/S1470-2045(20)30441-1

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More